1
|
Raza A, Chohan TA, Sarfraz M, Chohan TA, Imran Sajid M, Tiwari RK, Ansari SA, Alkahtani HM, Yasmeen Ansari S, Khurshid U, Saleem H. Molecular modeling of pyrrolo-pyrimidine based analogs as potential FGFR1 inhibitors: a scientific approach for therapeutic drugs. J Biomol Struct Dyn 2023; 41:14358-14371. [PMID: 36898855 DOI: 10.1080/07391102.2023.2187638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Accepted: 02/10/2023] [Indexed: 03/12/2023]
Abstract
Fibroblast growth factor receptors 1 (FGFR1) is an emerging target for the development of anticancer drugs. Uncontrolled expression of FGFR1 is strongly associated with a number of different types of cancers. Apart from a few FGFR inhibitors, the FGFR family members have not been thoroughly studied to produce clinically effective anticancer drugs. The application of proper computational techniques may aid in understanding the mechanism of protein-ligand complex formation, which may provide a better notion for developing potent FGFR1 inhibitors. In this study, a variety of computational techniques, including 3D-QSAR, flexible docking and MD simulation followed by MMGB/PBSA, H-bonds and distance analysis, have been performed to systematically explore the binding mechanism of pyrrolo-pyrimidine derivatives against FGFR1. The 3D-QSAR model was generated to deduce the structural determinants of FGFR1 inhibition. The high q2 and r2 values for the CoMFA and CoMSIA models indicated that the created 3D-QSAR models could reliably predict the bioactivities of FGFR1 inhibitors. The computed binding free energies (MMGB/PBSA) for the selected compounds were consistent with the ranking of their experimental binding affinities against FGFR1. Furthermore, per-residue energy decomposition analysis revealed that the residues Lys514 in catalytic region, Asn568, Glu571 in solvent accessible portion and Asp641 in DFG motif exhibited a strong tendency to mediate ligand-protein interactions through the hydrogen bonding and Van Der Waals interactions. These findings may benefit researchers in gaining better knowledge of FGFR1 inhibition and may serve as a guideline for the development of novel and highly effective FGFR1 inhibitors.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Ali Raza
- College of Pharmacy, The University of Lahore, Lahore, Pakistan
| | - Tahir Ali Chohan
- Institute of Pharmaceutical Sciences (IPS), University of Veterinary and Animal Sciences (UVAS), Lahore, Pakistan
| | - Muhammad Sarfraz
- College of Pharmacy, Al Ain University, Al Ain, United Arab Emirates
| | - Talha Ali Chohan
- Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan
| | - Muhammad Imran Sajid
- Center for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, Irvine, CA, USA
| | - Rakesh Kumar Tiwari
- Center for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, Irvine, CA, USA
| | - Siddique Akber Ansari
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Hamad M Alkahtani
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Shabana Yasmeen Ansari
- Pharmaceutical Unit, Department of Electronics, Chemistry and Industrial Engineering, University of Messina, Messina, Italy
| | - Umair Khurshid
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab, Pakistan
| | - Hammad Saleem
- Institute of Pharmaceutical Sciences (IPS), University of Veterinary and Animal Sciences (UVAS), Lahore, Pakistan
| |
Collapse
|
2
|
Zhang Y, Yu N. Design, Synthesis and Biological Evaluation: 5-amino-1H-pyrazole-1- carbonyl derivatives as FGFR Inhibitors. LETT DRUG DES DISCOV 2020. [DOI: 10.2174/1570180817999200608140628] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Background:
Fibroblast growth factors (FGFs) and their high affinity receptors (FGFRs)
play a major role in cell proliferation, differentiation, migration, and apoptosis. Aberrant FGFR signaling
pathway might accelerate development in a broad panel of malignant solid tumors. However,
the full application of most existing small molecule FGFR inhibitors has become a challenge due to
the potential target mutation. Hence, it has attracted a great deal of attention from both academic and
industrial fields for hunting for novel FGFR inhibitors with potent inhibitory activities and high selectivity.
Objective:
Novel 5-amino-1H-pyrazole-1-carbonyl derivatives were designed, synthesized, and
evaluated as FGFR inhibitors.
Methods:
A series of 5-amino-1H-pyrazole-1-carbonyl derivatives were established by a condensation
of the suitable formyl acetonitrile derivatives with either hydrazine or hydrazide derivatives in
the presence of anhydrous ethanol or toluene. The inhibitory activities of the target compounds were
screened against the FGFRs and two representative cancer cell lines. Tests were carried out to observe
the inhibition of 8e against FGFR phosphorylation and downstream signal phosphorylation in
human gastric cancer cell lines (SNU-16). The molecular docking of all the compounds were performed
using Molecular Operating Environment in order to evaluate their binding abilities with the
corresponding protein kinase.
Results:
A series of 5-amino-1H-pyrazole-1-carbonyl derivatives have been designed and synthesized,
screened for their inhibitory activities against FGFRs and cancer cell lines. Most of the target
compounds showed moderate to good anti-proliferate activities against the tested enzymes and cell
lines. The most promising compounds 8e suppressed FGFR1-3 with IC50 values of 56.4, 35.2, 95.5 nM,
and potently inhibited the SNU-16 and MCF-7 cancer cells with IC50 values of 0.71 1.26 μM, respectively.
And 8e inhibited the growth of cancer cells containing FGFR activated by multiple mechanisms. In
addition, the binding interactions were quite similar in the molecular models between generated
compounds and Debio-1347 with the FGFR1.
Conclusion:
According to the experimental findings, 5-amino-1H-pyrazole-1-carbonyl might serve
as a promising template of an FGFR inhibitor.
Collapse
Affiliation(s)
- Yan Zhang
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China
| | - Niefang Yu
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China
| |
Collapse
|
3
|
Recent advance in the development of novel, selective and potent FGFR inhibitors. Eur J Med Chem 2020; 186:111884. [DOI: 10.1016/j.ejmech.2019.111884] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Revised: 11/12/2019] [Accepted: 11/12/2019] [Indexed: 12/28/2022]
|
4
|
Volynets G, Lukashov S, Borysenko I, Gryshchenko A, Starosyla S, Bdzhola V, Ruban T, Iatsyshyna A, Lukash L, Bilokin Y, Yarmoluk S. Identification of protein kinase fibroblast growth factor receptor 1 (FGFR1) inhibitors among the derivatives of 5-(5,6-dimethoxybenzimidazol-1-yl)-3-hydroxythiophene-2-carboxylic acid. MONATSHEFTE FUR CHEMIE 2019. [DOI: 10.1007/s00706-019-02493-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
5
|
Wang X, He Q, Wu K, Guo T, Du X, Zhang H, Fang L, Zheng N, Zhang Q, Ye F. Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3. Eur J Med Chem 2019; 179:218-232. [PMID: 31254923 DOI: 10.1016/j.ejmech.2019.06.017] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Revised: 06/04/2019] [Accepted: 06/04/2019] [Indexed: 12/13/2022]
Abstract
Sustained activation of STAT3 is closely related to the cancer development, but the inhibitors for STAT3 overexpression are still in the clinical research stage. In this study, a series of 2,6-disubstituted purine derivatives were designed and synthesized, and their biological activities, as small molecule inhibitors of STAT3, were assessed. Compound PD26-TL07 exhibited remarkable antiproliferative activity against three cancer cell lines (IC50 values for HCT-116, SW480 and MDA-MB-231 were 1.77 ± 0.35, 1.51 ± 0.19, and 1.25 ± 0.38 μM, respectively). Moreover, detailed biological assays revealed that PD26-TL07 could effectively inhibited STAT3 phosphorylation, and had little inhibition to others'. The newly discovered PD26-TL07 displayed an expecting anticancer effect both in vitro and in vivo. The molecular docking models revealed that PD26-TL07 could bind to the SH2 domain of STAT3. Three additional compounds (PD26-BZ01, PD26-TL03 and PD26-AS06) were also able to inhibit this phosphorylation. This study described novel 2,6-disubstituted purine derivatives as potent anticancer agents targeting STAT3.
Collapse
Affiliation(s)
- Xuebao Wang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
| | - Qin He
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
| | - Kaiqi Wu
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
| | - Taoning Guo
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
| | - Xuze Du
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
| | - Huan Zhang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
| | - Longcheng Fang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
| | - Nan Zheng
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
| | - Qihong Zhang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
| | - Faqing Ye
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
| |
Collapse
|
6
|
Zheng YY, Feng KX, Xia AB, Liu J, Tang CK, Zhou ZY, Xu DQ. Merging catalyst-free synthesis and iodine catalysis: one-pot synthesis of dihydrofuropyrimidines and spirodihydrofuropyrimidine pyrazolones. RSC Adv 2019; 9:9770-9776. [PMID: 35520709 PMCID: PMC9062170 DOI: 10.1039/c9ra01665a] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Accepted: 03/18/2019] [Indexed: 11/21/2022] Open
Abstract
A new and efficient one-pot strategy combining catalyst-free synthesis and iodine catalysis has been developed for the synthesis of dihydrofuropyrimidines and spirodihydrofuropyrimidine pyrazolones. This approach affords products in moderate to high yields (up to 96%) with excellent diastereoselectivities (up to >25 : 1 dr). The reaction is simple to carry out and is metal-free. A new and efficient one-pot strategy combining catalyst-free synthesis and iodine catalysis has been developed for the synthesis of dihydrofuropyrimidines and spirodihydrofuropyrimidine pyrazolones.![]()
Collapse
Affiliation(s)
- Ya-Yun Zheng
- Catalytic Hydrogenation Research Centre
- State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology
- Zhejiang University of Technology
- Hangzhou
- China
| | - Kai-Xiang Feng
- Catalytic Hydrogenation Research Centre
- State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology
- Zhejiang University of Technology
- Hangzhou
- China
| | - Ai-Bao Xia
- Catalytic Hydrogenation Research Centre
- State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology
- Zhejiang University of Technology
- Hangzhou
- China
| | - Jie Liu
- Catalytic Hydrogenation Research Centre
- State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology
- Zhejiang University of Technology
- Hangzhou
- China
| | - Cheng-Ke Tang
- Catalytic Hydrogenation Research Centre
- State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology
- Zhejiang University of Technology
- Hangzhou
- China
| | - Zhan-Yu Zhou
- Catalytic Hydrogenation Research Centre
- State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology
- Zhejiang University of Technology
- Hangzhou
- China
| | - Dan-Qian Xu
- Catalytic Hydrogenation Research Centre
- State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology
- Zhejiang University of Technology
- Hangzhou
- China
| |
Collapse
|
7
|
Yu T, Yang Y, Liu Y, Zhang Y, Xu H, Li M, Ponnusamy M, Wang K, Wang JX, Li PF. A FGFR1 inhibitor patent review: progress since 2010. Expert Opin Ther Pat 2016; 27:439-454. [PMID: 27976968 DOI: 10.1080/13543776.2017.1272574] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION FGFR1 is a well known molecular target for anticancer therapy. Many studies have proved that the regulation of FGFR1 activity is a promising therapeutic approach to treat a series of cancers. Therefore, the development of potent inhibitors has consequently become a key focus in the present drug discovery, and it is encouraging that several highly selective FGFR1 inhibitors have been identified from various sources in recent years. Areas covered: This article reviews patents and patent applications related to selective FGFR1 inhibitors published from 2010 to 2016. This summary highlights about 15 patents from different pharmaceutical companies and academic research groups. We used Baidu and NCBI search engines to find relevant patents as a search term. Expert opinion: In the past few years, considerable progress has been made in the identification and development of selective FGFR1 inhibitors in use. At present, at least 10 inhibitors of FGFR1 are in clinical trials, and several agents have shown encouraging results under experimental conditions. Given the fact that FGFR1 plays a crucial role in the regulation of cancer and other diseases, we hope that it will gain further attraction from pharmaceutical companies and encourage development of more novel, safe and efficient FGFR1 inhibitors in the future.
Collapse
Affiliation(s)
- Tao Yu
- a Institute for Translational Medicine , Qingdao University , Qingdao , People's Republic of China
| | - Yanyan Yang
- a Institute for Translational Medicine , Qingdao University , Qingdao , People's Republic of China
| | - Yan Liu
- b Food and Drug Administration of Linyi City , Hedong District Branch , Linyi , People's Republic of China
| | - Yinfeng Zhang
- a Institute for Translational Medicine , Qingdao University , Qingdao , People's Republic of China
| | - Hong Xu
- c Department of Orthodontics , Affiliated Hospital of Qingdao University , People's Republic of China
| | - Mengpeng Li
- a Institute for Translational Medicine , Qingdao University , Qingdao , People's Republic of China
| | - Murugavel Ponnusamy
- a Institute for Translational Medicine , Qingdao University , Qingdao , People's Republic of China
| | - Kun Wang
- a Institute for Translational Medicine , Qingdao University , Qingdao , People's Republic of China
| | - Jian-Xun Wang
- a Institute for Translational Medicine , Qingdao University , Qingdao , People's Republic of China
| | - Pei-Feng Li
- a Institute for Translational Medicine , Qingdao University , Qingdao , People's Republic of China
| |
Collapse
|
8
|
Kim JH, Kwak Y, Song C, Roh EJ, Oh CH, Lee SH, Sim T, Choi JH, Yoo KH. Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line. Bioorg Med Chem Lett 2016; 26:5082-5086. [PMID: 27599742 DOI: 10.1016/j.bmcl.2016.08.076] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Revised: 08/18/2016] [Accepted: 08/24/2016] [Indexed: 10/21/2022]
Abstract
A novel series of arylurea and arylamide derivatives 1a-z, 2a-d having aminoquinazoline scaffold was designed and synthesized. Their in vitro antiproliferative activities against RT112 bladder cancer cell line and inhibitory activities against FGFR3 kinase were tested. Most compounds showed good antiproliferative activities against RT112 bladder cancer cell line, and arylurea compounds 1a-z were more potent than arylamide compounds 2a-d. Among them, eight compounds 1a, 1d-g, 1l, 1y, and 1z showed potent activities with GI50 values below submicromolar range. Especially, arylurea compounds 1d and 1g possessing 2,3-dimethyl and 3,4-dimethyl moieties exhibited superior or similar antiproliferative activity (GI50=8.8nM and 30.2nM, respectively) to AZD4547 (GI50=29.2nM) as a reference standard.
Collapse
Affiliation(s)
- Jung Hun Kim
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea; Department of Chemistry, Hanyang University, Seoul 133-791, Republic of Korea
| | - Yeonui Kwak
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - Chiman Song
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - Eun Joo Roh
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - Chang-Hyun Oh
- Center for Biomaterials, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - So Ha Lee
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - Taebo Sim
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - Jung Hoon Choi
- Department of Chemistry, Hanyang University, Seoul 133-791, Republic of Korea
| | - Kyung Ho Yoo
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea.
| |
Collapse
|
9
|
Liu Z, Yu S, Chen D, Shen G, Wang Y, Hou L, Lin D, Zhang J, Ye F. Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1. DRUG DESIGN DEVELOPMENT AND THERAPY 2016; 10:1489-500. [PMID: 27217720 PMCID: PMC4861610 DOI: 10.2147/dddt.s88587] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
FGFR1 is well known as a molecular target in anticancer drug design. TKI258 plays an important role in RTK inhibitors. Utilizing TKI258 as a lead compound that contains a quinazolinone nucleus, we synthesized four series of 3-vinyl-quinoxalin-2(1H)-one derivatives, a total of 27 compounds. We further evaluated these compounds for FGFR1 inhibition ability as well as cytotoxicity against four cancer cell lines (H460, B16-F10, Hela229, and Hct116) in vitro. Some compounds displayed good-to-excellent potency against the four tested cancer cell lines compared with TKI258. Structure–activity relationship analyses indicated that small substituents at the side chain of the 3-vinyl-quinoxalin-2(1H)-one were more effective than large substituents. Lastly, we used molecular docking to obtain further insight into the interactions between the compounds and FGFR1.
Collapse
Affiliation(s)
- Zhiguo Liu
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China
| | - Shufang Yu
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China
| | - Di Chen
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China
| | - Guoliang Shen
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China
| | - Yu Wang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China
| | - Leping Hou
- Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of China
| | - Dan Lin
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China
| | - Jinsan Zhang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China
| | - Faqing Ye
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China
| |
Collapse
|
10
|
Wang X, Chen D, Yu S, Zhang Z, Wang Y, Qi X, Fu W, Xie Z, Ye F. Synthesis and Evaluation of Biological and Antitumor Activities of Tetrahydrobenzothieno[2,3-d]Pyrimidine Derivatives as Novel Inhibitors of FGFR1. Chem Biol Drug Des 2016; 87:499-507. [PMID: 26575787 DOI: 10.1111/cbdd.12687] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Revised: 08/27/2015] [Accepted: 10/02/2015] [Indexed: 01/12/2023]
Abstract
A series of tetrahydrobenzothieno[2,3-d]pyrimidine derivatives were designed, synthesized, and evaluated as inhibitors of FGFR1. These analogs were synthesized via Gewald's reaction under mild conditions. The structures of the synthesized compounds were characterized by spectroscopic data (IR, (1) H NMR and MS). Their antitumor activities were evaluated against H460, A549 and U251 cell lines in vitro. Results revealed that the tested compounds showed moderate antitumor activities. Structure-activity relationship analyses indicated that compounds with an aromatic ring substituted in the C-2 position or with larger molecules such as 3g, 4c, and 7 were more effective than others. The compound, 3g (78.8% FGFR1 inhibition at 10 μm), was identified to have the most potent antitumor activities, with IC50 values of 7.7, 18.9, and 13.3 μm against the H460, A549, and U251 cell lines, respectively. Together, the results suggested that tetrahydrobenzothieno[2,3-d]pyrimidine derivatives may serve as a potential agent for the treatment of FGFR1-mediated cancers.
Collapse
Affiliation(s)
- Xuebao Wang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China
| | - Di Chen
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China
| | - Shufang Yu
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China
| | - Zaikui Zhang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China
| | - Yu Wang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China
| | - Xiaolu Qi
- Yichang Humanwell Pharmaceutical Co., Ltd, Yichang, 443005, China
| | - Weitao Fu
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China
| | - Zixin Xie
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China
| | - Faqing Ye
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China
| |
Collapse
|